Does Insurance Cover Wegovy? State-by-State Breakdown
Wegovy insurance coverage in 2026: which major carriers cover it, what prior authorization looks like, and how Medicaid coverage varies by state.
By Nora Bissett, Pricing Editor
Our methodology sets out how these guides get researched and kept current.
Looking for a provider? Our 2026 comparison of the leading GLP-1 telehealth sellers is a click away.
GLP-1 Insurance Coverage: Medicare, Medicaid & Commercial →Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Does insurance cover Wegovy? Sometimes. It depends on who's writing your plan, what state you live in, and whether you have a qualifying medical history. In 2026, a minority of commercial plans cover Wegovy for obesity treatment, Medicare covers it only in narrow cases, and Medicaid varies wildly state by state. Below are the major carriers, the typical prior authorization requirements, and a state-by-state Medicaid breakdown.
For a straight answer about *your* plan, nothing beats the phone. Ring member services (the number is on your insurance card) and ask narrowly: "Is Wegovy on my formulary for obesity treatment? What's the prior authorization requirement?" Formularies change quarterly, and your insurer is the only definitive source.
Key Takeaways
- A minority of commercial plans cover Wegovy for obesity in 2026, usually with prior authorization.
- Medicare Part D plans may cover Wegovy for its cardiovascular indication (added to the label in 2024). For weight management, Part D patients who qualify can get it for $50/month through the temporary Medicare GLP-1 Bridge.
- Medicaid covers Wegovy for obesity in about 10 states, with strict PA requirements, and the number has been falling.
- TRICARE covers Wegovy with PA for TRICARE Prime and TRICARE Select beneficiaries meeting BMI criteria; other TRICARE plans lost weight-loss drug coverage on August 31, 2025.
- Prior authorization nearly always turns on two things: documented prior weight-loss attempts, and BMI at ≥30 (or ≥27 with a comorbidity).
- Appeals can work when the patient meets the plan's criteria.
The Big Picture
Commercial insurance coverage for weight-loss medications has grown steadily since Wegovy's 2021 approval, but it's still a minority of plans. A few structural reasons:
- Employers drive coverage. Most commercial plans are employer-sponsored, and employers have been slow to add GLP-1 obesity coverage because of the cost (Wegovy's list price comes to about $16,000 a year per employee before rebates).
- The 2024 cardiovascular indication changed the math. Once SELECT put the reduction in cardiovascular events at 20%, payers began treating "cardiovascular risk reduction" as a different question from "obesity," and covering the two differently.
- GLP-1 drug rebates are opaque. Pharmacy benefit managers (PBMs) negotiate rebates with Novo Nordisk that can knock 30–50% off list price, but those rebates don't always flow to patients.
For cost specifics if you're covered (or not), see our real cost of Wegovy breakdown.
Major Commercial Carriers
Coverage varies by specific plan within each carrier, but these are the 2026 patterns we see most often:
| Carrier | Typical Wegovy coverage | PA required |
|---|---|---|
| Blue Cross Blue Shield | Varies by licensee and employer; some have dropped it | Yes |
| UnitedHealthcare | On the commercial drug list; some employer groups exclude it | Yes |
| Aetna | Covers for obesity on most commercial plans | Yes |
| Cigna | Covers on most commercial plans with PA | Yes |
| Humana | Limited commercial coverage; Medicare Advantage excludes it for weight loss | Yes |
| Anthem | Varies by Anthem plan and state | Yes |
| Kaiser Permanente | Restricted on Kaiser commercial formularies | Yes |
Blue Cross Blue Shield
BCBS is a federation of 33 independent companies, not one plan. Coverage for Wegovy varies dramatically by licensee and by employer. Blue Cross Blue Shield of Michigan's fully insured large-group plans, for example, stopped paying for GLP-1 weight-loss drugs on January 1, 2025, while many self-funded employer groups still cover them. Check your specific plan in our Blue Cross Blue Shield insurance guide.
UnitedHealthcare
UnitedHealthcare, through OptumRx, keeps Wegovy (injection and tablet) on its commercial drug list with PA, with a first authorization typically lasting 5 months. Whether your plan covers it depends on the drug list your employer chose, and some employer groups exclude weight-loss-only GLP-1s. See our UnitedHealthcare insurance guide.
Aetna and Cigna
Both carriers cover Wegovy for obesity on most commercial plans with PA, and CVS Caremark, Aetna's pharmacy benefit manager, named Wegovy its preferred commercial GLP-1 in July 2025. Typical PA includes BMI ≥30 or ≥27 with comorbidity, plus documentation of at least 3 months of prior lifestyle intervention. See our Aetna insurance guide and Cigna insurance guide.
Medicare: Mostly No
The block on Medicare Part D is statutory. Under the Medicare Modernization Act of 2003, no drug can be covered when its use is for weight loss, weight gain or anorexia. That clause kept phentermine, and the older weight-loss drugs with it, outside Medicare Part D since the program began in 2006.
The workaround, as of 2024, is the cardiovascular indication. After SELECT, the FDA widened Wegovy's label: it now covers cutting heart attacks, strokes and cardiovascular deaths in any adult who has established cardiovascular disease as well as obesity or overweight. CMS then told Part D plans they may pay for Wegovy on this indication, while obesity on its own remains outside what they can cover.
In practice, if you have Medicare and a documented history of heart attack, stroke, or established coronary artery disease, you may qualify for Wegovy coverage under your Part D plan. Without that cardiovascular history, the route is the Medicare GLP-1 Bridge, temporary and set to run from July 2026 until the end of 2027: Part D patients prescribed Wegovy for weight management who meet its criteria, including prior authorization, pay $50/month. See our Medicare insurance guide for more.
Medicaid: Varies by State
Medicaid coverage for Wegovy is the most complex piece of this picture because each state's Medicaid program sets its own drug formulary. In January 2026, KFF put the number of state Medicaid programs paying for GLP-1s as obesity treatment at 13, and several have dropped coverage since. The rough state-by-state picture from our state Medicaid data, last reviewed in August 2026:
States Covering Wegovy for Obesity (approximate, as of August 2026)
| State | Coverage | Notes |
|---|---|---|
| Delaware | Yes | Covered with PA |
| Kansas | Yes | Covered with PA |
| Michigan | Yes | Covered with PA |
| Minnesota | Yes | Covered with PA |
| Mississippi | Yes | Covered with PA |
| Missouri | Yes | Covered with PA |
| North Carolina | Yes | Ended October 2025, reinstated December 2025 |
| Tennessee | Yes | Covered with PA |
| Virginia | Yes | Covered with PA |
| Wisconsin | Yes | Covered with PA |
| Rhode Island | Ending | Scheduled to end October 1, 2026 |
States That Have Ended Coverage
California (Medi-Cal) and Pennsylvania ended adult weight-loss coverage on January 1, 2026, and New Hampshire and South Carolina have also ended it. Utah's pilot expired on June 30, 2026, and Massachusetts ended coverage on July 1, 2026.
States NOT Covering Wegovy for Obesity
Most remaining states either exclude GLP-1 drugs for weight management entirely, or cover Ozempic/Mounjaro only for diagnosed type 2 diabetes. This includes Texas, Florida, Georgia, Ohio, Alabama, Arizona, Louisiana, and most of the Mountain West.
This list changes frequently. States add and remove GLP-1 coverage based on Medicaid budget pressures. Verify current status with your state Medicaid program directly. The KFF analysis of Medicaid GLP-1 coverage is the best publicly maintained source.
TRICARE
TRICARE covers weight-loss medications, including Wegovy, with PA for TRICARE Prime and TRICARE Select beneficiaries who meet BMI criteria (≥30 or ≥27 with comorbidity). As of August 31, 2025, beneficiaries in other TRICARE plans, such as TRICARE For Life, no longer have weight-loss drug coverage. PA is processed through Express Scripts, the TRICARE pharmacy benefit manager. Typical turnaround is 3–7 days.
Typical Prior Authorization Requirements
Most Wegovy PAs, regardless of carrier, ask for the same documentation:
- BMI at ≥30 on its own, or ≥27 where a weight-related comorbidity accompanies it
- Comorbidity documentation where BMI falls in the 27–29.9 band (sleep apnea, dyslipidemia, cardiovascular disease, hypertension or type 2 diabetes)
- A prior weight loss attempt, typically 3–6 months of diet and exercise, evidenced in provider notes
- No contraindications, such as severe GI disease, pancreatitis, MEN-2, or medullary thyroid carcinoma in the patient or the family
- Reauthorization at 6 or 12 months, carrying documented weight loss of ≥5%
Do's and Don'ts for Getting Approved
Do:
- Start the PA process with complete documentation on day one
- Ask your prescriber's office to include measured BMI and comorbidities in the PA
- Appeal any denial; overturn rates are surprisingly high
- Keep a weight log during your prior lifestyle intervention
- Call your insurer's member services line to verify your formulary before filling; it is the only authoritative source
Don't:
- Assume coverage without verifying; call the number on your insurance card
- Skip the prior lifestyle intervention documentation; this is the #1 denial reason
- Use GoodRx as your primary backup (see Wegovy cost)
- Ignore the manufacturer's savings card and self-pay prices; they're a better fallback than paying retail
What to Do If You're Denied
- Request the denial letter in writing with the specific reason.
- File an appeal within the timeframe specified (usually 60–180 days). Include additional clinical notes, labs, and a letter of medical necessity from your prescriber.
- External review. If the internal appeal fails, most states allow an independent external review by a third-party reviewer. This is free and binding on the insurer.
- Explore alternatives. If appeals fail, Novo Nordisk sells Wegovy for cash: $149–$299/month for the pill and $349/month for the pen ($399 for 7.2 mg). See manufacturer coupons or compounded semaglutide options in our best providers ranking.
If the denial stands and you end up paying cash, a health savings or flexible spending account may still help. Some compounded GLP-1 sellers say their plans can be paid that way: Injectco, Levers Health and Lttl describe their plans as HSA/FSA eligible, as do Omzo and Prescriva. Rejuve Meds lists HSA/FSA eligibility too, on plans paid a year up front.
Velvet Rx, TeleHealth Med and Lean Rx say they accept HSA and FSA cards. Whether a purchase qualifies is set by your own plan, so keep the receipt.
Bottom Line
Insurance coverage for Wegovy in 2026 is a minority outcome. A minority of commercially insured patients will get coverage with prior authorization; the rest will pay out of pocket or switch to compounded semaglutide. Medicare and Medicaid coverage is limited and state-dependent. The most useful single step is to check the formulary before you commit to any treatment path: call the number on your insurance card and ask whether Wegovy is covered for obesity.
If you're not covered, don't give up: Novo Nordisk's self-pay price, compounded semaglutide through a trusted telehealth provider, and an appeal of an initial denial all remain viable paths. For the full pricing picture across every scenario, see our real cost of Wegovy guide.
Sources & methodology — as of October 2026
- 1.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 2.KFF — Employer Health Benefits Annual Survey— Kaiser Family Foundation.
- 3.CMS — Medicare Part D Prescription Drug Coverage Program— Centers for Medicare & Medicaid Services.
- 4.KFF — Medicare Spending on GLP-1 Drugs (Ozempic, Wegovy, Mounjaro, Zepbound)— Kaiser Family Foundation.
- 5.U.S. Department of Labor — ERISA and Employer Health Plans— U.S. Department of Labor, Employee Benefits Security Administration.
- 6.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
Compare the sellers
Ready to compare GLP-1 providers?
Trust, support, availability, the medications carried and what they cost — we rank every major telehealth seller on all five, and refresh it each quarter. Nothing padded.
GLP-1 Insurance Coverage: Medicare, Medicaid & Commercial →Related guides
The Real Cost of Wegovy: Insurance, GoodRx, and Manufacturer Coupons Compared
How much does Wegovy actually cost in 2026? We break down list price, insurance co-pays, NovoCare self-pay, the Novo Nordisk savings card (for plans that cover Wegovy), GoodRx, and compounded alternatives side by side.
How to Pay for a GLP-1 Without Insurance: Savings Cards, Self-Pay and Compounded
Getting semaglutide, tirzepatide and other GLP-1s without insurance: compounded options, manufacturer coupons, and the cheapest legal paths.
Manufacturer Coupons for Ozempic, Wegovy, Mounjaro, and Zepbound
Current Novo Nordisk and Eli Lilly savings cards and self-pay prices for Wegovy (pen and pill), Ozempic, Zepbound (pen, KwikPen and vial), Mounjaro and Foundayo: who qualifies, what you pay, and the Medicare GLP-1 Bridge.
Read our methodology · affiliate disclosure · about us